Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Trial Profile

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Sponsors TARIS Biomedical
  • Most Recent Events

    • 19 Nov 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 1 Nov 2018.
    • 16 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 04 May 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top